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through CREB-binding Protein Recruitment and Autoregulation*
(Received for publication, November 4, 1997, and in revised form, December 12, 1997)
Hui Li and J. Don Chen‡
From the Department of Pharmacology and Molecular Toxicology, University of Massachusetts Medical School,
Worcester, Massachusetts 01655-0126
Transcriptional coactivators are involved in gene ac-
tivation by nuclear hormone receptors. The receptor-
associated coactivator 3 (RAC3) was recently identified
to be highly related to the steroid receptor coactivator-1
and transcriptional intermediate factor 2, thereby es-
tablishing a novel family of nuclear receptor coactiva-
tors. In this study, we identified a RAC3 fragment con-
taining three LXXLL motifs conserved among this
family, which is sufficient to mediate nuclear receptor
interaction in vivo and in vitro. Point mutations that
disrupt ligand-dependent activation function of the re-
ceptor inhibited the interaction. We found that a 162-
amino acid fragment of RAC3 conferred transcriptional
activation and recruited the CREB-binding protein and
that three distinct LXXLL motifs mediated the tran-
scriptional activation. A trimeric far Western analysis
demonstrated the formation of a ternary complex con-
taining CREB-binding protein, RAC3, and the receptor.
In addition, we showed that RAC3, transcriptional inter-
mediate factor 2, and steroid receptor coactivator-1 are
expressed in specific tissues and cancer cells and that
RAC3 transcript is directly up-regulated by retinoid
treatment. These results suggest that RAC3 may contrib-
ute to amplified transcriptional responses through both
recruitment of additional coactivators and autoregula-
tion by the receptor-coactivator complex.
Transcriptional regulation by nuclear receptors for steroids,
thyroid hormones (TR),1 retinoids (RAR), and vitamin D3 con-
trols key aspects of animal development, reproduction, home-
ostasis, and adult organ physiology (for reviews, see Refs. 1–5).
The nuclear receptors are characterized by a common domain
structure, including an N-terminal A/B region that contains
the first activation function (AF-1), a DNA binding domain
(DBD) responsible for recognition of specific DNA response
elements, and a C-terminal ligand binding domain. The ligand
binding domains of TR and RAR also mediate heterodimeriza-
tion with retinoid X receptor (RXR) (for review, see Ref. 2), and
such complexes are capable of repressing basal transcription in
the absence of ligand, while activating net transcription upon
ligand treatment (6). Although the mechanisms of such repres-
sion and activation functions are not fully understood, a grow-
ing list of cofactors that interact with and modulate the tran-
scriptional activation and repression properties of nuclear
receptors have been identified (for reviews, see Refs. 7–9).
The involvement of cofactors in nuclear receptor signaling
was first postulated when members of the nuclear receptor
superfamily were found to cross-react with each other function-
ally (10) and with other transcription factors (11). Currently,
several such cofactors have been identified biochemically (12–
16) and genetically (17, 18). In particular, two related proteins
known as the silencing mediator for RAR and TR (SMRT) and
the nuclear receptor corepressor (N-COR) were identified as
TR- and RAR-interacting proteins that can assist transcrip-
tional repression by the unliganded receptors (17–21). Re-
cently, SMRT and N-COR were found to form complexes with
the transcriptional corepressor mSin3 and the histone deacety-
lases HDAC1 and mRPD3 (22–24), suggesting that transcrip-
tional repression by SMRT and N-COR might involve histone
deacetylation (25, 26).
Hormone binding is thought to dissociate the corepressor
complex from nuclear receptors, allowing the receptors to re-
cruit coactivators, such as the CREB/E1A-binding proteins
(CBP/p300) (for review, see Ref. 27 and references therein), the
p300/CBP-associated factor (P/CAF; Ref. 28), and the steroid/
nuclear receptor coactivator (SRC) family proteins (for review,
see Ref. 9). In contrast to the nuclear receptor corepressor
complexes, all of these putative coactivators contain intrinsic
histone acetyltransferase (HAT) activity (29–31). Therefore,
transcriptional activation and repression by nuclear receptors
might be determined by the relative acetylation level of targets
common to nuclear receptor coactivators and corepressors. Re-
cent findings also suggest that, in addition to histones, these
coactivators may also acetylate and modulate the DNA binding
property of activator proteins or general transcription factors
(32, 33), suggesting the involvement of multiple targets and
pathways in transcriptional regulation.
The steroid/nuclear receptor coactivator gene family con-
tains the steroid receptor coactivator-1 (SRC-1; also known as
NCoA-1) (34–38), the transcriptional intermediate factor 2
(TIF2, also known as GRIP1) (39–41), and the receptor-asso-
ciated coactivator 3 (RAC3, also known as ACTR, p/CIP, and
AIB1) (42–44). Sequence comparison of these proteins reveals
that they share an overall identity of about 40%, but with
striking similarity at the N-terminal basic helix-loop-helix
(bHLH) and period-aryl hydrocarbon receptor-single minded
(PAS) “A” and “B” domains. The bHLH-PAS domain function in
protein-protein interactions, heterodimerization, and target
gene selection in many members of this family (45–47), but the
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role of this domain in the SRC family remains unclear. In
addition to the bHLH-PAS domain, seven highly conserved
motifs containing a LXXLL (L indicates hydrophobic residue)
core consensus sequence flanked by charged and conserved
residues are found in a central region that mediates both nu-
clear receptor interaction and transcriptional activation func-
tions of all three SRC proteins (42, 43, 48). These motifs are
also known as the leucine-charged domains (LCDs). Three of
these motifs in SRC-1 have been shown to mediate direct pro-
tein-protein interaction with liganded receptors (43, 48), sug-
gesting that these conserved motifs might play an important
role in the functions of these coactivators.
In this study, we further characterized the nuclear receptor
interaction and transcriptional activation domains of RAC3
and found that different LXXLL motifs are differentially in-
volved in either nuclear receptor interaction or transcriptional
activation, suggesting the importance of the flanking se-
quences in determining the function of these LXXLL motifs. We
showed that RAC3 interacts directly with CBP through its
activation domain and that RAC3 can form a bridge for the
interaction between CBP and nuclear receptors, suggesting
that one mechanism of transcriptional activation by these co-
activators is recruitment of additional cofactors. In addition,
we found that the RAC3 transcript is directly up-regulated by
retinoic acid, demonstrating a new and perhaps independent
mechanism of transcriptional coactivation by the nuclear re-
ceptor coactivators. Therefore, these results strongly suggest
that RAC3 plays an important role in nuclear receptor activa-
tion through utilization of multiple mechanisms.
MATERIALS AND METHODS
Plasmids—The individual RAC3 fragments were obtained by either
restriction enzyme digestion of the full-length RAC3 clone or by PCR
amplification with synthetic primers harboring suitable cloning sites.
The LXXLL motif constructs were generated by subcloning annealed
double-stranded oligonucleotides encoding the specified amino acids
into the yeast expression vector pAS1 (49). Detailed information regard-
ing these constructs is available at http://146.189.26.74/. All other con-
structs have been previously published (18, 28, 39, 42, 50, 51) .
Far Western Analysis—GST fusion proteins were overexpressed and
purified from DH5a cells on glutathione-agarose beads. The fusion
proteins were separated on denaturing protein gels (SDS-polyacryl-
amide gel electrophoresis) and electroblotted onto nitrocellulose filters
in a transfer buffer (25 mM Tris-HCl, pH 8.3, 192 mM glycine, 0.01%
SDS). After denaturation in 6 M guanidine hydrochloride, the proteins
were renatured by stepwise dilution of guanidine hydrochloride to 0.187
M in HB buffer (25 mM Hepes, pH 7.7, 25 mM NaCl, 5 mM MgCl2, 1 mM
dithiothreitol). The filters were then saturated with blocking buffer (5%
nonfat milk and then 1% milk in HB buffer plus 0.05% Nonidet P-40).
In vitro translated 35S-labeled proteins were generated in reticulocyte
lysate (Promega) and were diluted into a hybridization buffer (20 mM
Hepes, pH 7.7, 75 mM KCl, 0.1 mM EDTA, 2.5 mM MgCl2, 0.05% Nonidet
P-40, 1% milk, 1 mM dithiothreitol). The filters were allowed to
hybridize overnight at 4 °C followed by three washes with hybrid-
ization buffer. The bound 35S-labeled proteins were detected by
autoradiography.
Yeast Two-hybrid Assay—The yeast two-hybrid assay was carried
out in the yeast Y190 strain (49). The GAL4 DBD fusion constructs were
generated in the pGBT9 vector, and the GAL4 activation domain (AD)
fusion constructs were made in the pGAD424 or pACTII vector (CLON-
TECH). The b-galactosidase activities were determined with the ONPG
liquid assay as described previously (52).
Cell Culture and Transient Transfection—African green monkey kid-
ney CV-1 cells were grown at 37 °C in 5% CO2 in Dulbecco’s modified
Eagle’s medium supplemented with 10% resin-charcoal stripped fetal
bovine serum, 50 units/ml penicillin G, and 50 mg/ml streptomycin
sulfate. One day prior to transfection, cells were plated in 24-well
culture dishes at a density of 50,000 cells/well. Transfection was per-
formed by standard calcium phosphate precipitation. All transfection
experiments were performed in triplicate and were replicated at least
once. Twelve hours after transfection, cells were washed with PBS and
refed fresh medium containing the indicated amounts of ligand. After
30 h, cells were harvested and b-galactosidase and luciferase activities
were assayed as described previously (52).
Luciferase and b-Galactosidase Assay—Transfected cells in each well
were lysed as described (52) and processed for the luciferase and the
b-galactosidase assays. The lysates were transferred into 96-well mi-
crolite plates for luciferase assay and 96-well microtiter plates for
b-galactosidase assay as described (52). The luciferase activities were
determined with a MLX microtiter plate luminometer (Dynex) using
100 ml of assay solution (0.1 M KPO4, 5 mM ATP, 10 mM MgCl2) and 100
ml of luciferin solution (0.01 M D-luciferin in 0.1 M KPO4, pH 7.8). The
luciferase activities were normalized to the b-galactosidase activity
expressed from the cotransfected pCMX-bGal plasmid.
Northern Blot Analysis—Cells were treated with different concentra-
tions of atRA (0, 10, 100, or 1000 nM) for a period of 12 h. In the control
group, cells were treated with an equal volume of solvent (80% EtOH
plus 20% DMSO). Total RNAs were isolated using an RNA isolation kit
(RNAzol) and separated on a 1% agarose gel with 2.2 M formaldehyde
and blotted onto nitrocellulose filters. Filters were hybridized with
random-primed 32P-labeled DNA probes specific for RAC3, TIF2, and
SRC-1 in hybridization buffer (50% formamide, 53 SSPE (13 SSPE is
0.18 M NaCl, 10 mM NaPO4, and 1 mM EDTA at pH 7.7), 23 Denhardt’s
solution, 0.1% SDS, 0.1 mg of sheared herring sperm DNA/ml) at 42 °C
overnight. The final wash was in 13 SSC (0.15 M NaCl plus 0.015 M
sodium citrate)-0.1% SDS at 65 °C. Filters were exposed to x-ray film at
270 °C for about 24 h. The human tissue and cancer cell blots were
purchased from CLONTECH and hybridized according to manufactur-
er’s protocols.
RESULTS
RAC3-Nuclear Receptor Interaction—The nuclear receptor-
interacting domain of RAC3 has been previously located within
a central fragment between amino acids 401 and 1204 (42).
Here, we show that deletion of amino acids 507–1017 elimi-
nates the receptor interaction and that the rest of the N-
terminal and C-terminal sequences cannot interact with ligan-
ded RAR (Fig. 1A) or other class II receptors (data not shown)
in the yeast two-hybrid system, suggesting that amino acids
507–1017 contain the interacting domain. The interaction was
then confirmed by the mammalian two-hybrid system, in which
amino acid fragments 401–800 and 613–752 both interact with
RAR, whereas fragments 401–695 and 401–624 do not interact
with the receptor (Fig. 1B). We found that the 613–752 frag-
ment can also interact significantly with the unliganded recep-
tor, and such interaction was only slightly enhanced by ligand,
whereas the interaction with fragment 401–800 is ligand-de-
pendent. Coincident with previous studies (43, 48), this recep-
tor-interacting domain (RID) of RAC3 contains three LXXLL
motifs, which have been implicated in mediating direct inter-
action between SRC-1 and nuclear receptors (43, 48). To fur-
ther confirm the interactions between RAC3-RID and nuclear
receptors, we generated a GST-RID fusion and analyzed its
interaction with three nuclear receptors in vitro by far Western
blot analyses. Significant interactions were observed with li-
ganded RAR, TR, and estrogen receptor (Fig. 1C), demonstrat-
ing that this RID domain indeed mediates a ligand-dependent
interaction between RAC3 and nuclear receptors.
Point Mutations of the AF2-AD That Abolish RAC3 Interac-
tion—We have demonstrated previously that the interaction
between RAC3 and nuclear receptor depends on the presence of
an intact AF2-AD (42). Here, we further tested whether the
AF-2 function per se is required for such interaction. Several
point mutations within the AF2-AD helix of the human RXRa
(51) were analyzed for their effects on interaction with RAC3.
We found that disruption of the AF-2 function by three inde-
pendent AF2-AD point mutations (F450A, F450P, and
ML454A) abolishes the interaction between RAC3 and RXR
(Fig. 1D). In contrast, a neutral AF2-AD mutation (M452A)
permits a strong ligand-dependent interaction. These results
suggest that the activation function of the AF2-AD helix cor-
relates with its ability to interact with RAC3, further support-
ing the hypothesis that RAC3 is an AF-2-dependent nuclear
receptor coactivator.



















Three Conserved LXXLL Motifs Activate Transcription—The
transcriptional AD of RAC3 was previously located within
amino acids 401–1204 (42). Further deletional analyses in
yeast cells reveal that the AD of RAC3 is located at the C
terminus of this central fragment (Fig. 2A), in contrast to the
receptor-interacting domain found at the N terminus. In par-
ticular, amino acids 401–800 and further deletion mutants
cannot activate transcription from a Gal4-dependent b-galac-
tosidase reporter, whereas the C-terminal fragments 982–
1204, 982–1056, and 1017–1179 strongly stimulate the re-
porter gene expression (Fig. 2A). These results demonstrate a
mutations disrupt RAC3 interaction. The interactions between RAC3
and AF2-AD point mutants were determined in the yeast two-hybrid
system. The RAC3.1 fragment was expressed as a GAL4 AD fusion,
whereas RXR mutants were expressed as GAL4 DBD fusions. The
b-galactosidase activities were determined from three transformants in
the absence (open bars) or presence (closed bars) of 1 mM 9-cis-RA.
FIG. 1. RAC3-nuclear receptor interaction. A, the indicated
RAC3 fragments, with starting and ending amino acids shown in the
parentheses, are expressed as GAL4 AD fusions in the yeast pGAD424
vector. Individual pGAD-RAC3 constructs were cotransformed with a
pGBT-F.RAR construct, which expresses a GAL4 DBD-full-length
hRARa fusion. Relative b-galactosidase activities were determined
from three independent transformants in the absence (open bars) or
presence (closed bars) of 1 mM atRA. The corresponding RAC3 domains
are shown at the top as described previously (42). bHLH-PAS, basic
helix-loop-helix-Per/Ahr/Sim domain; i–vi, the LXXLL motifs; Q, the
polyglutamine tract. B, the indicated RAC3 fragments were expressed
as GAL4 DBD fusions in the pCMX-Gal vector (52) and cotransfected
together with a VP16-RAR fusion construct that expresses a VP16
AD-full-length hRARa fusion. Relative luciferase activities were deter-
mined from three independent transfections in the absence (open bars)
or presence (closed bars) of 1 mM atRA. i, ii, and iii indicate the three
LXXLL motifs. C, interaction of RAC3 with nuclear receptors in vitro.
The purified GST module (GST) and the GST-RAC3-RID (RID) fusion
were separated by SDS-polyacrylamide gel electrophoresis and ana-
lyzed by far Western analyses for interaction with 35S-labeled hRARa,
hTRb, and hERa in the absence (2) or presence (1) of 1 mM cognate
ligands. The positions of the intact GST-RAC3-RID fusion proteins
are marked with asterisks. T3, 3,5,39-triiodo-L-thyronine; E2,
17b-estradiol; RA, all-trans retinoic acid. D, receptor AF2-AD point
FIG. 2. The RAC3 activation domain. A, transcriptional activation
by RAC3 in mammalian cells. The indicated RAC3 fragments were
expressed as GAL4 DBD fusions in the pCMX-Gal vector. The relative
fold induction was determined by comparison with the pCMX-Gal vec-
tor. B, three individual LCD motifs activate transcription. The indi-
cated RAC3 fragments or individual motifs were expressed as GAL4
DBD fusions in the yeast Y190 cells, and the b-galactosidase units were
determined from three independent transformants.



















minimal RAC3-AD between amino acids 1017 and 1179. Within
the RAC3-AD, we found several conserved LXXLL motifs. Be-
cause these motifs are not required for nuclear receptor inter-
action, we speculate that they might be directly involved in
transcriptional activation. We analyzed the activation function
of each of these motifs and found that when fused with the
GAL4 DBD, the three C-terminal motifs (iv, v, and vi), but not
the N-terminal ones, can activate transcription from a Gal4-
dependent luciferase reporter in yeast cells (Fig. 2B). These
results indicate that these C-terminal LXXLL motifs may di-
rectly mediate transcriptional activation by RAC3.
RAC3 Interacts with CBP and Nuclear Receptors Simulta-
neously—Because SRC-1 can interact with the general tran-
scriptional coactivator CBP and p300 (37), we tested whether
RAC3 can also interact with CBP. Serial GST-CBP fusions
covering the SRC-1-interacting domain were analyzed for in-
teractions with 35S-labeled full-length RAC3, SRC-1, and
RAC3-AD (amino acids 1017–1179) (Fig. 3, A–C). We find that
RAC3 interacts strongly with the CBP fragments C and D but
not with other fragments. Similarly, SRC-1 interacts with CBP
fragments C and D, consistent with previous observations (36,
37). We also find that the RAC3-AD alone is sufficient for CBP
interaction, suggesting that one function of AD is to recruit
CBP or its related proteins.
The ability of RAC3 to interact with both CBP and nuclear
receptors prompted us to test whether each pair of interactions
is enough to mediate the formation of a ternary complex. We
developed a trimeric far Western protocol to test this possibility
(Fig. 3D). Briefly, the CBP fragments C and D were probed first
with unlabeled full-length RAC3 and then with 35S-labeled
nuclear receptor. The results demonstrate that RAC3 can
bridge the interaction between CBP and RAR in the presence of
ligand (Fig. 3E) but not in the absence of ligand (not shown). As
controls, CBP fragments C and D were probed parallel with
35S-RAC3 and 35S-RAR, individually. These results suggest
that the strength of interactions between CBP-RAC3 and
RAC3-RAR are sufficient to link together a ternary complex.
These results also confirm that RAC3 utilizes distinct domains
for interaction with CBP and RAR.
RAC3 Is Expressed in a Tissue- and Cancer Cell-specific
Manner—The expression patterns of RAC3 in different human
tissues and cancer cells were examined and compared with
those of SRC-1 and TIF2. RAC3 is expressed at high levels in
the heart, placenta, skeletal muscle, and pancreas but at very
low levels in the brain, lung, liver, and kidney (Fig. 4A, left).
The SRC-1 message is expressed at high levels in the heart,
brain, placenta, skeletal muscle, and pancreas and, again, at
extremely low levels in the lung, liver, and kidney. Two distinct
SRC-1 messages are clearly detectable, and the larger message
appears to be expressed at a higher level than the smaller form.
The expression pattern of TIF2 is very similar to that of RAC3,
but with the highest expression in the heart instead of pla-
centa. In the human cancer cells, we found the highest expres-
sion of the RAC3 message in the Burkitt’s lymphoma Raji cells
FIG. 3. RAC3 interacts with CBP
and forms a ternary complex with
CBP and RAR. A, schematic diagram of
the CBP domain structure and CBP frag-
ments (A–F) (28). The various factors that
interact with each CBP domain are shown
at the top. NR, nuclear receptors; Bromo,
bromodomain; Zn, zinc finger domain; Q,
glutamine. B, Coomassie Blue staining of
the purified GST-CBP fusion proteins.
Lanes A–F correspond to the CBP frag-
ments A–F shown in panel A. C, interac-
tion of RAC3, RAC3-AD, and SRC-1 with
CBP fragments in far Western analyses.
The input probes used in each experiment
are shown at the left. D, schematic dia-
gram of the trimeric far Western protocol.
E, RAC3 forms a complex with CBP and
RAR simultaneously in the trimeric far
Western blot. The arrow indicates the
CBP-RAC3-RAR ternary complex.



















and substantial expression in the epitheloid carcinoma HeLa
cells, the chronic myelogenous leukemia K-562 cells, the colo-
rectal adenocarcinoma SW480 cells, and the melanoma G361
cells. Low levels of RAC3 were found in promyelocytic leukemia
HL-60 cells, the lymphoblastic leukemia MOLT-4 cells, and the
lung carcinoma A549 cells. These results indicate that RAC3
expression varies greatly in different tissues and cancer cells.
In contrast, the SRC-1 transcript is highly expressed only in
K-562 cells and SW480 cells and not in the Raji cells. The
expression pattern of TIF2 is very similar to that of RAC3, with
the highest expression level in the Raji cells. Together, these
results suggest that the expression of the SRC family genes is
highly variable in different tissues and cell types, suggesting
that members of this coactivator family might have distinct
roles in different cell types.
RAC3 Expression Is Up-regulated by Retinoic Acid—The ex-
pression of nuclear receptor genes is frequently regulated by
cognate hormones and, in particular, autoregulation of the
RAR gene expression by atRA has been clearly demonstrated
(53). Because RAC3 is involved in transcriptional activation of
the receptor, we speculated that the expression of coactivator
might be also under regulation by the ligand-receptor-coacti-
vator complex. We analyzed the effect of atRA on RAC3 gene
expression in the HL-60 cells and found that atRA significantly
enhanced the expression of RAC3 in a concentration-dependent
manner (Fig. 4B). Induction of the RAC3 transcript was most
obvious at a concentration between 1028 and 1027 M of atRA
and was not sensitive to inhibition of de novo protein synthesis.
Similar up-regulation of RAC3 expression was also found in the
acute promyelocytic leukemic NB4 cells (data not shown).
These results suggest not only that RAC3 can function as an
RAR coactivator but also that its expression is autoregulated
by the receptor-coactivator complex (Fig. 4C).
DISCUSSION
We show here that the nuclear receptor coactivator RAC3
utilizes a 140-amino acid domain to interact with liganded
nuclear receptors and a C-terminal 162-amino acid domain to
activate transcription, as well as to interact with CBP, and that
the three C-terminal LXXLL motifs are sufficient for transcrip-
tional activation. We demonstrate that RAC3, SRC-1, and TIF2
are expressed in a tissue-specific manner and that the expres-
sion of RAC3 can be up-regulated by retinoic acid. These find-
ings have extended our and others’ previous observations (42–
44) and suggest that individual LXXLL motifs might contribute
differently for receptor interaction and transcriptional activa-
tion. Our results suggest that RAC3 may enhance transcrip-
tional activation of nuclear receptors through a combination of
recruiting additional coactivators as well as autoregulation.
As RAC3 was initially characterized, several laboratories
simultaneously reported the cloning of similar coactivators
that are known as p/CIP (43), ACTR (44), and AIB1 (54).
Comparison of these five sequences reveals that they are en-
coded by the same gene and that the differences should be due
allelic variation. In particular, RAC3 and AIB1 share over
99.9% identity, with only two subtle differences, including a
change in the length of the polyglutamine (poly-Q) tract (29
residues in AIB1 and 26 in RAC3). RAC3 and ACTR share
FIG. 4. Expression patterns of
RAC3, SRC-1, and TIF2 in human tis-
sues and cancer cells. A, human multi-
ple tissue (left) and cancer cell (right)
Northern blots were first hybridized with
a 32P-RAC3 DNA probe and then rehy-
bridized with 32P-SRC-1 and then with
32P-TIF2 probes. Between each rehybrid-
ization, the membranes were exposed to
x-ray film to ensure appropriate stripping
of the earlier probe. Note that SRC-1
transcripts show different patterns from
that of RAC3 and TIF2, indicating the
absence of cross-contamination from each
hybridization. B, total RNA (20 mg) of
HL-60 cells treated with indicated con-
centrations of atRA for 12 h or with 1 mM
tRA plus 10 mM cycloheximide (CHX)
were analyzed for RAC3 message by
Northern blot analysis (top panel). The
position of the RAC3 transcript is indi-
cated by an arrow. Ethidium bromide
staining of the gel confirms that each lane
contains an equal amount of RNA (bottom
panel). C, model of the receptor-coactiva-
tor autoregulation. After ligand binding,
the RXR-RAR heterodimer recruits a co-
activator complex that contains members
of the SRC family proteins CBP/p300 and
p300/CBP-associated factor. This coacti-
vator complex functions as an acetylator
machinery that acetylates histones and
disrupts nucleosome structure, allowing
the access of basal transcriptional ma-
chinery to the core promoter. Because
both RAR and RAC3 transcripts are ele-
vated by RA treatment, the increased con-
centration of the two key proteins should
further amplify the transcriptional re-
sponses, leading to a high level of gene
induction.



















about 99.6% identity with several differences, including a 10-
amino acid insertion at residues 321 and a 15-amino acid
deletion between residues 902 and 918 of RAC3. RAC3 and the
mouse p/CIP share only 77.6% identity with three major dif-
ferences, including two unrelated gaps at amino acids 172–199
and 1296–1402, as well as the relative position of the poly-Q
tract. Although the function of this poly-Q domain remains
unclear, similar sequences are also found in many transcrip-
tional regulators, and the elongation of the poly-Q tract ap-
pears to correlate with human disease (55), suggesting that the
poly-Q tract within these three might have a functional impli-
cation yet to be established.
Our data suggest that the three N-terminal LXXLL motifs of
RAC3 are likely involved in nuclear receptor interaction, con-
sistent with recent studies with SRC-1 and p/CIP (43, 48), in
which the individual motifs were found to be sufficient for
nuclear receptor interaction. However, our attempts to demon-
strate protein-protein interaction of each of the three RAC3
motifs with nuclear receptors were not successful (data not
shown), suggesting that these motifs might act synergistically
to stabilize the interaction if they indeed mediate such inter-
action. In contrast, we found that the three C-terminal motifs
are sufficient to activate transcription. These results suggest
that the conserved LXXLL consensus per se is insufficient to
determine the function of these motifs and that specific struc-
tural constraints, perhaps defined by the neighboring residues,
are important in determining their function.
It was recently shown that ACTR and SRC-1 both possess
intrinsic HAT activity (31, 44). ACTR and SRC-1 preferentially
acetylate histones H3 and H4, both in the free form and in the
mononucleosome (31, 44). Comparison of the diacetyl H3 pep-
tides suggests that Lys-9 and Lys-14 of histone H3 are the
preferred sites for SRC-1 acetylation (31). Similarly, H3 is also
a preferred substrate for ACTR (44), but the target residues
remain unknown. Because histone acetylation has been corre-
lated with gene activation (56, 57), these findings suggest that
histone acetylation might be critical for gene activation by
nuclear receptors. It remains unclear whether individual acety-
lases in the putative coactivator complex could modify histones
in a redundant manner or whether different HAT enzymes are
used for modification of distinct residues. In the latter case,
such differential acetylation events might result in synergistic
transcriptional activation. Alternatively, it was shown recently
that the general coactivator CBP/p300 can also acetylate the
sequence-specific tumor suppressor p53 and that such acetyla-
tion promotes DNA binding by p53 (32). It will be interesting to
determine whether nuclear receptors can be acetylated and
their DNA bindings regulated by these coactivators.
The expression patterns of RAC3, TIF2, and SRC-1 appear to
be tissue- and cancer cell-specific, suggesting that the normal
function of these coactivators might be limited to certain tis-
sues and cells. The observed expression patterns of SRC family
genes in the present study are different from earlier reports
that used mouse tissues (37, 38, 41, 43). This might reflect a
more selective expression of the SRC family in human tissues
than in rodent tissues. The expression pattern of this family of
genes in normal tissues is relatively similar, whereas the pat-
terns between RAC3 and SRC-1 in cancer cells vary substan-
tially. Lung carcinoma A549 cells appear to express none of the
three coactivators, consistent with the lack of expression of
these three genes in normal lung tissue. Correspondingly, lung
carcinoma is resistant to the antitumor properties of retinoid
treatment (58, 59). Interestingly, RAC3 and TIF2, but not
SRC-1, are highly expressed in the Burkitt’s lymphoma Raji
cells, and all three SRC genes are highly expressed in the
colorectal carcinoma SW480 cells. The mechanism of this over-
expression is unclear. It will be interesting to determine
whether such overexpression contributes to neoplastic pheno-
type of these cancer cells and whether any of these coactivators
are amplified in these cells, analogous to amplification of AIB1
in the breast cancer cells (54).
Autoregulation has long been established as a mechanism
that contributes significantly to the high level of gene induction
by retinoids (53). For instance, atRA treatment induces RARb
gene expression, and an RAR response element was subse-
quently identified in the promoter region of this gene (60).
Therefore, the binding of atRA to endogenous RAR is expected
to activate expression of the receptor gene itself, thereby rais-
ing the level of the receptor and amplifying the effect of the
ligand. This form of autoregulation is expected to play an
important role in RA-dependent pattern formation and mor-
phogenesis. It is now known that RAR is not the only factor
responsible for such feedback control of gene activation. This
study demonstrates that expression of the coactivator RAC3 is
also increased by atRA treatment in at least two different RA
responsive cancer cells. Thus, simultaneous enhancement of
receptor and coactivator gene expression may both contribute
to the formation an activator complex that stimulates gene
expression upon ligand treatment. It remains to be determined
whether the expression of RAC3 and other related genes can
also be regulated by other hormones. In conclusion, this study
suggests that transcriptional activation by nuclear receptor
might be the result of a combined effect of coactivator recruit-
ment and autoinduction of multiple effector genes.2
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